Michael J. Mack

“

The rapid growth of TAVR among patients in their 60s reflects how treatment options for aortic valve disease are evolving. For younger patients, the decision extends beyond the initial procedure. Valve durability, the potential need for future interventions, and a lifetime treatment strategy should be central to discussions between each patient and the multidisciplinary Heart Team that helps determine the most appropriate treatment.

Michael E. Farkouh

Interventional / Structural Cardiology · Cedars-Sinai Smidt Heart Institute

7d

“

Our study report supports the use of CABG surgery over PCT; however the results should not be overly simplified. The management of patients with diabetes and coronary disease should still be personalized to include an assessment of surgical risk and benefits as well as patient preferences.

“

These results further support the indication for percutaneous MV repair in patients with primary MR who are at high risk for surgery, accepting that patients treated commercially are different to those enrolled in EVEREST II—they are older, are more frail, and have higher surgical risk estimates.

Joanna Chikwe

Cardiac Surgery · University of California, Riverside

3w

“

It was, I think, a surprise to everybody how a failed MitraClip takes a surgical repair off the table and 95% of these patients end up with a mitral valve replacement.

Federico M. Asch

Cardiac Imaging · Boston University

2mo

“

While we learned that patients with higher pulmonary hypertension are at higher risk after they receive the MitraClip, they still do better than if they would not have had the intervention done. Doing an echocardiogram is critical in determining if a patient is a good candidate for MitraClip and in following these patients to evaluate results of the procedure in the long run.

Molly Szerlip

Interventional Cardiology · Northwestern University

2mo

“

When we see dialysis patients, we really take into account why they are on dialysis. The person who has polycystic kidney disease and is on dialysis is very different than the person who has diabetes, peripheral vascular disease, and hypertension. So we really look at the cause of their dialysis and try to assess what the 1- or 2-year mortality is without aortic stenosis.